Incyte INCY announced that the FDA has approved the label expansion of Opzelura (ruxolitinib) cream 1.5%. Opzelura, a topical ...

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens ...

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

The "Topical Drugs Packaging Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has ...

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough ...

Doctors have shared their top tips for travelling with eczema, offering some wise words for people who find heading to ...

Dermatologist highlights cosmeceutical products useful in the management of acne, atopic dermatitis, and melasma.

Eczema, or atopic dermatitis, often worsens during seasonal changes like monsoon and autumn. Fluctuating humidity, allergens, and infections can trigger flare-ups.

Microneedling may help hair loss by stimulating hair growth at the hair follicle, especially when combined with other topical ...

The most effective treatments for eczema accomplish three things: They calm inflammation, bring relief from itch and restore ...